Show simple item record

dc.contributor.authorXue, Cong
dc.contributor.authorHu, Zhihuang
dc.contributor.authorJiang, Wei
dc.contributor.authorZhao, Yuanyuan
dc.contributor.authorXu, Fei
dc.contributor.authorHuang, Yan
dc.contributor.authorZhao, Hongyun
dc.contributor.authorWu, Jingxun
dc.contributor.author吴敬勋
dc.contributor.authorZhang, Yang
dc.contributor.authorZhao, Liping
dc.contributor.authorZhang, Jing
dc.contributor.authorChen, Likun
dc.contributor.authorZhang, Li
dc.date.accessioned2013-02-28T08:26:20Z
dc.date.available2013-02-28T08:26:20Z
dc.date.issued2012-08
dc.identifier.citationLUNG CANCER,2012,77(2):371-375zh_CN
dc.identifier.issn0169-5002
dc.identifier.urihttp://dx.doi.org/10.1016/j.lungcan.2012.04.014
dc.identifier.uriWOS:000307036500022
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/15005
dc.description.abstractIntroduction: Treatment choice for NSCLC in China has not previously been reported. This paper explores the clinical practice and adherence to treatment guidelines for NSCLC. Methods: A specifically designed questionnaire was used. It consisted of personal information of the responders and treatment details (patient identification data was excluded). Questionnaires were delivered to doctors in 12 major cities in China. Doctors were asked to answer the questionnaires based on real cases in their daily practice. Results: 987 cases of NSCLC were included. In first-line chemotherapy, regimens were mostly platinum-based among which gemcitabine plus platinum was predominately used (27.4%), followed by docetaxel plus platinum (16.2%) and paclitaxel plus platinum (13.5%). In second-line therapy some were treated with single agents, such as docetaxel (12.9%), gefitinib (11.1%), pemetrexed (9.3%), and erlotinib (3.5%). 44.5% were with doublet therapy. Detection rate of epidermal growth factor receptor (EGFR) mutation was only 9.6% because of the limited prevalence of testing technology. EGFR mutation rate was 46.8%. EGFR-tyrosine kinase inhibitors (TKIs) were used more frequently as salvage (14.8%) rather than upfront therapy (5.3%). Conclusions: This survey reveals the daily clinical treatment for NSCLC in China. Overall data showed modest adherence to the national guideline (NCCN guideline Chinese version) for first-line chemotherapy. We believe this survey is valuable to provide a reference for further clinical trial design and policy making. (C) 2012 Elsevier Ireland Ltd. All rights reserved.zh_CN
dc.description.sponsorshipSanofi aventis; Science and Technology Commission of Guangzhou [2010J-E151]; Wu Jieping Medical Foundation [08-JC-003]zh_CN
dc.language.isoenzh_CN
dc.publisherELSEVIER IRELAND LTDzh_CN
dc.subjectChemotherapyzh_CN
dc.subjectChinese populationzh_CN
dc.subjectEpidermal growth factor receptorzh_CN
dc.subjectNon-small cell lung cancerzh_CN
dc.subjectPractice patternzh_CN
dc.subjectSurveyzh_CN
dc.titleNational survey of the medical treatment status for non-small cell lung cancer (NSCLC) in Chinazh_CN
dc.typeArticlezh_CN


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record